£1.5m Precision Medicine funding


Professor Louis Chesler

We're proud to announce £1.5m Precision Medicine funding for targeted, less toxic cancer treatments.

Initiative Leader, Professor Louis Chesler of The Institute of Cancer Research

A new programme for young cancer patients

This is ground-breaking funding to develop a new UK programme for young cancer patients 

We're providing £1.5m funding to advance Precision Medicine in the UK, to make this field of treatment a reality for children and young adults diagnosed with cancer.

Our ambition is that all children, teenagers and young adults diagnosed with cancer in the UK have access to Precision Medicine through the NHS.Our Chief Executive, Cliff O’Gorman, says:

“Our ambition is that all children, teenagers and young adults diagnosed with cancer in the UK have access to Precision Medicine through the NHS. This ground-breaking funding will help develop the first programme for Precision Medicine for young cancer patients in the UK, already started in parts of the USA and Europe.”

What is Precision Medicine?

Precision Medicine is an exciting new way to deliver cancer treatment to children. It takes into account individual variations in genes, environment and lifestyle.

Precision therapies target specific changes in individual patients’ tumour DNA, allowing for more effective treatments while reducing toxic side effects.

It has huge potential to improve cure rates and reduce the burden of toxicity on young cancer patients - through better targeted chemotherapy, introducing advances in immunotherapy and using other evolving technologies.

Professor Louis Chesler of The Institute of Cancer Research, says:

“This funding will help us move towards a more comprehensive and structured approach to genetic testing to match children with cancer to specific targeted treatments, which could be an incredibly important step towards increasing survival and reducing the side-effects of treatment.”                     

"One way to think about Precision Medicine is that we now have drugs that attack single cancer causing proteins. They don't interfere with any
normal cells or normal proteins, they just attack the tumour and they just attack the one gene or protein that really matters."

Bringing Precision Medicine to young cancer patients in the UK

This treatment approach to young cancer patients has been applied in parts of the USA and Europe with some success. But, until now, efforts in the UK have been somewhat ad hoc – largely due to lack of development funding in the NHS.

We want to drive forward the implementation of Precision Medicine for young cancer patients in the UK.

Watch our 'Little Translators' Louis and Grace as they explain Professor Louis Chesler's research.

Read more: Louis' appeal 

Where your money goes

Hover over a segment for details

NCRI AMRC